-
Mashup Score: 1Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi - 2 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3Exploring the Safety and Efficacy of EPI-7386 in Combination with Enzalutamide in mCRPC - Ronald Tutrone - 2 month(s) ago
Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Exploring the safety and efficacy of EPI-7386 in combination with enzalutamide in #mCRPC. @RTutrone @ChesUrology and @zklaassen_md discuss the promising data surrounding EPI-7386 and the potential of EPI-7386 to change the treatment landscape > https://t.co/TjqopJSZdd @EssaPharma https://t.co/I3Jh3stu6N
-
-
Mashup Score: 82023 Key Learnings in mCRPC Treatments – Alicia Morgans - 2 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Rana R. McKay, Medical Oncologist, Associate Professor,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 9
Jacob Orme and Emmanuel Antonarakis discuss their study on the use of PARP inhibitors in metastatic prostate cancer patients with BRCA2 and SPOP mutations. Dr. Antonarakis shares the study’s genesis, rooted in his clinical observation of exceptional responses to PARP inhibitors in patients with these mutations. The study, involving 131 patients across 13 international sites, reveals that…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice - Mark Fleming - 3 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Real World Evidence Evaluating the Underutilization of Treatments for mCRPC in Clinical Practice – Mark Fleming Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Mark Fleming, MD, GU Disease Committee Chair, Sarah Connon Research Institute, President, Virginia Oncology…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Unlocking the Future of mCRPC Treatment: Exploring Immune Checkpoint Inhibitors for MMR Loss and MSI-High - Sumit Subudhi - 3 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Sumit K. Subudhi, Associate Professor, Department of Genitourinary Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 6
Rana McKay hosts Andrew Laccetti to discuss advancements in metastatic castration-resistant prostate cancer (mCRPC) treatments. Dr. Laccetti highlights the Phase I/II trial of masofaniten combined with enzalutamide, a novel hormonal therapy for mCRPC. Masofaniten, a first-in-class N-terminal ligand antagonist for the androgen receptor, shows promise in overcoming resistance to current hormonal…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4
ASCO GU 2024 The ProstACT GLOBAL phase 3 study aims to investigate the effectiveness and safety of the addition of 177Lu-DOTA-rosopatamab to the best standard of care for patients with metastatic castration-resistant prostate cancer expressing PSMA
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
ProstACT GLOBAL: A phase 3 study of best SoC with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing #mCRPC progressing despite prior treatment with a novel androgen axis drug. Presented by Neel Patel @TelixPharma > https://t.co/KUoP3hTj9P @zklaassen_md https://t.co/W1S0mqP1Xg
-
-
Mashup Score: 3Exploring the Safety and Efficacy of EPI-7386 in Combination with Enzalutamide in mCRPC - Ronald Tutrone - 3 month(s) ago
Zach Klaassen and Ron Tutrone explore the promising data surrounding EPI-7386, an inhibitor of the androgen receptor. The conversation focuses on the phase two trial of EPI-7386 in combination with enzalutamide for treating metastatic castrate-resistant prostate cancer. Dr. Tutrone explains the unique mechanism of action of EPI-7386, which targets the N-terminal domain of the androgen receptors,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Exploring the safety and efficacy of EPI-7386 in combination with enzalutamide in #mCRPC. @RTutrone @ChesUrology and @zklaassen_md discuss the promising data surrounding EPI-7386 and the potential of EPI-7386 to change the treatment landscape > https://t.co/TjqopJSZdd @EssaPharma https://t.co/I3Jh3stu6N
-
-
Mashup Score: 82023 Key Learnings in mCRPC Treatments – Alicia Morgans - 3 month(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, Massachusetts Rana R. McKay, Medical Oncologist, Associate Professor,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
Unlocking the future of #mCRPC treatment: Exploring immune checkpoint inhibitors for MMR loss and MSI-high. Sumit Subudhi @MDAndersonNews joins Neal Shore, MD, FACS @CURCMB in this independent medical education initiative supported by @LoxoLillyOnc > https://t.co/rEKbzQ0dMo https://t.co/bxG3MNSAgw